Clinical Trial Update: Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating adjunctive donepezil therapy and genetic risk factors associated with cognitive dysfunction in brain tumor survivors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor
• Cognitive Dysfunction

Drugs mentioned

• Donepezil (donepezil)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Brain Tumor, Brain Cancer | Phase 1 | Status: COMPLETED